Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q3 FY25 results · Oct–Dec 2024
Sun Pharma Advanced Research Company reported revenue from operations of ₹14.91 crore (up 7.6% from Q3 FY24) and net loss of ₹79.51 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 14.91 | 13.86 | +7.6% | 12.86 | +15.9% |
| Other income | 0.19 | 6.39 | −97.0% | 0.04 | +375.0% |
| Total income | 15.10 | 20.25 | −25.4% | 12.90 | +17.1% |
| Profit before tax | (79.44) | (99.65) | Loss narrowed | (107.17) | Loss narrowed |
| Net profit for the period | (79.51) | (99.65) | Loss narrowed | (107.33) | Loss narrowed |
| EPS, basic (₹) | (2.45) | (3.07) | Loss narrowed | (3.31) | Loss narrowed |
| Net margin (%) | -533.3 | -719.0 | -834.6 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 14.91 | 13.86 | +7.6% | 12.86 | +15.9% |
| Other income | 0.19 | 6.39 | −97.0% | 0.04 | +375.0% |
| Total income | 15.10 | 20.25 | −25.4% | 12.90 | +17.1% |
| Profit before tax | (79.71) | (99.65) | Loss narrowed | (107.69) | Loss narrowed |
| Net profit for the period | (79.71) | (99.65) | Loss narrowed | (107.69) | Loss narrowed |
| EPS, basic (₹) | (2.46) | (3.07) | Loss narrowed | (3.32) | Loss narrowed |
| Net margin (%) | -534.6 | -719.0 | -837.4 |
Consolidated
- Filed with BSE
- 10 Feb 2025, 20:18 IST
- Board meeting
- 10 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Feb 2025, 20:18 IST
- Board meeting
- 10 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE